Minus 35C: fully automated warehouse for blood plasma

Jungheinrich has implemented a comprehensive intralogistics concept in Dublin, Ireland, for the global healthcare company Grifols.
One of the special features is a cold store warehouse with a capacity for 1,152 pallets and a temperature range of down to minus 35 degrees Celsius, suitable for the safe stacking and retrieval of blood plasma.
The stacker crane, which is specially configured for use in extreme temperature conditions, reaches a height of 14.3 metres. Jungheinrich also designed special quadruple-depth storage channels for Grifols. The load is handled crossways by a double shuttle.
The second single-aisle, high-bay silo warehouse is set to a temperature of plus 5 degrees Celsius and can accommodate 2,972 pallets. The stacker crane operating here reaches a ceiling height of up to 26 metres.
The entire warehouse complex in Dublin was designed for the transport and safe storage of medical devices on both Euro and US pallets (1219 x 1016 mm) and is controlled by the Jungheinrich Warehouse Control System (WCS). The new automated system is arranged to reliably meet the high demands for storage technology and safety that are inherent in the storage of delicate blood plasma and medical devices. In order to meet these demands, Jungheinrich’s comprehensive intralogistics installation covered all of the administrative processes in Grifols medical supply chain as well as the compulsory final quality controls.

‘Thrucool’ launched for pharmaceutical shipments

Singapore Airlines (SIA) has announced the launch of Thrucool, a new service to transport high-value, time-sensitive and temperature-controlled pharmaceutical cargo.
Thrucoolis a set of dedicated cold chain services to safeguard the integrity of pharmaceutical and healthcare shipments during air transport. These include priority uplift and handling, quick ramp transfers at airports, cold room facilities, as well as thermal blankets and covers for crucial insulation from external factors. Customers can also opt to place shipments in temperature-controlled containers, and track their location during shipping.
SIA has partnered with terminal operators SATS, Cargologic and Qantas Freight to launch a ‘quality corridor’ along the Zurich-Singapore-Sydney route as an initial service. Complying with standards adopted from the IATA CEIV Pharma1 program, the quality corridor addresses the industry’s need for safety, care and efficiency in the transport of pharmaceutical and healthcare products. This reduces the potential for product loss attributed to handling and environmental factors such as temperature excursions during carriage.

US firm to buy Australian pharma company PPP

Pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced its intent to acquire Australia-based Pharmaceutical Packaging Professionals (PPP). The acquisition of PPP, a provider of clinical trial manufacturing, packaging, storage and distribution services, is designed to establishe a presence for PCI in Australia, viewed as pivotal to continued growth and expansion in the Asia Pacific region. Australia is one of the leading countries for Phase 1 studies globally, and with this acquisition, PPP’s Phase I offering also enables PCI to better support customers from early phases of clinical development through to commercial launch.
Located in Melbourne, Victoria, Australia, PPP is active in clinical trial supply with a comprehensive suite of support services including early clinical phase sterile and non-sterile drug manufacture of investigational medicines, packaging and labelling services for investigational products, as well as logistical services including storage and distribution to global investigational sites. PPP’s expertise supports projects across a range of temperature conditions including controlled room temperature, 2-8˚C, -20˚C, and -80˚C environments, which expands PCI’s existing capabilities in storing, packaging, and shipping Cold Chain products. Experiencing significant demand for its services, PPP is currently undertaking a facility expansion and upgrade to add additional storage and distribution services, labelling and packaging rooms, Grade D manufacturing as well as sterile-fill manufacturing capabilities for Phase II clinical studies.
PPP’s services complements PCI’s global portfolio of clinical and commercial services, including clinical and commercial scale drug manufacturing, packaging and labelling of clinical trial medicines, global logistical services to investigational sites and commercial contract packaging services. PPP’s strong market presence with Phase I units as well as the company’s geographic reach and experience working with US, European, and Asia Pacific customers in countries including China, Korea, Vietnam, Sri Lanka, Taiwan, Malaysia, Thailand and New Zealand, will allow PCI to continue to grow its capabilities in the region.
“The addition of PPP is significant for our continued global expansion,” said Bill Mitchell, president and CEO of PCI Pharma Services. “The Asia-Pacific region, including Australia, is a very attractive and growing segment in the clinical trials market. Our customers continue to seek new markets both for execution of their clinical studies as well as partners that can support them through the supply chain.”

©2019 All Rights Reserved. MHD Magazine is a registered trademark of Prime Creative Media.